Leerink Partners analyst Whit Mayo maintains $HCA Healthcare (HCA.US)$ with a buy rating, and adjusts the target price from $396 to $460.
According to TipRanks data, the analyst has a success rate of 50.0% and a total average return of 3.9% over the past year.
Furthermore, according to the comprehensive report, the opinions of $HCA Healthcare (HCA.US)$'s main analysts recently are as follows:
The anticipated disturbances from hurricanes were factored in, however, a more notable revelation was the projection for EBITDA and EPS in 2025 falling short of market expectations, interrupting a sequence of strong beat and raise events. Despite the attractive nature of the recent 9% stock dip, there is a belief that a phase of stock consolidation might be forthcoming.
HCA Healthcare's Q3 outcomes have successfully navigated through the negative impacts of hurricanes, a trend which is anticipated to persist into Q4 and potentially lead to FY2024 guidance aligning with the lower spectrum of projections. Even with ongoing challenges from hurricanes, the company's leadership anticipates earnings growth in 2025 to meet or exceed their longstanding objectives, bolstered by an admissions growth forecast of 3%-4%, which is considered above the usual trend.
Following the release of 3Q24 results, there has been an update to the financial model for HCA Healthcare. Despite high expectations prior to the third quarter results, the company's underlying performance remained robust, demonstrated by a 7.1% increase in same-store revenues, compared to the third quarter of the previous year's 7.9%.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
Leerink Partners分析師Whit Mayo維持$HCA醫療 (HCA.US)$買入評級，並將目標價從396美元上調至460美元。
根據TipRanks數據顯示，該分析師近一年總勝率為50.0%，總平均回報率為3.9%。
此外，綜合報道，$HCA醫療 (HCA.US)$近期主要分析師觀點如下：
颶風預期的干擾已被考慮進去，然而，更加引人注目的是2025年EBITDA和每股收益低於市場預期，打破了一系列強勁的超預期和提高事件。儘管最近股價下跌了9%，具有吸引力，但有人認爲股票整合階段可能即將來臨。
hca醫療的Q3結果成功地應對了颶風的負面影響，這一趨勢預計將持續到Q4，並可能導致FY2024的指引與預期的下限保持一致。即使受到颶風的持續挑戰，該公司領導層預計2025年的盈利增長將達到或超過他們長期設定的目標，這得到了入院增長預測爲3%-4%的支撐，被視爲高於通常的趨勢。
在發佈第三季度24年第3季度業績後，hca醫療的財務模型已經更新。儘管在第三季度業績公佈前市場對其寄予厚望，但公司的基礎表現依然強勁，同店銷售收入增加了7.1%，而上一年同期增長了7.9%。
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
